CLINICAL TRIALS WITH HALOFANTRINE HYDROCHLORIDE IN MALAWI
Identifieur interne : 000A55 ( Istex/Corpus ); précédent : 000A54; suivant : 000A56CLINICAL TRIALS WITH HALOFANTRINE HYDROCHLORIDE IN MALAWI
Auteurs : J. Wirima ; M. E. Molyneux ; C. Khoromana ; H. M. GillesSource :
- The Lancet [ 0140-6736 ] ; 1988.
English descriptors
- Teeft :
- Abdominal pain, Airway epithelium, American society, Arterial pressure, Cell count, Clinical trials, Comparable efficacy, Cure rate, Diluent solution, Dwangwa, Falciparum, Falciparum chloroquine, Falciparum malana, First part, First study, Frusemide, Haemoglobin level, Halofantrine, Halofantrine hydrochloride, Inhaled, Inhaled corticosteroids, Inhaled frusemide, Laboratory data, Lake malawi, Lung diseases, Malawi, Older children, Oral frusemide, Parasitaemia, Parasite, Parasite counts, Phenanthrene methanol compound halofantrine, Phenanthrene methanol halofantrine, Placebo, Plasmodium, Plasmodium falciparum, Protective effect, Pulse rate, Random order, Recrudescence rate, Resistant strains, Same time intervals, Second part, Second screening test, Second trial, Single dose, Study days, Tanzanian border, Tropical medicine, Typical history, West shore, Younger children.
Abstract
Abstract: Two clinical trials of the phenanthrene methanol compound halofantrine in the treatment of Plasmodium falciparum were conducted in Malawi, in areas where the parasite was known to be chloroquine resistant. In the first trial all 46 patients had symptoms of malaria and parasite densities ranging from 2500/μl to 212 000/μl. They were given a single dose of halofantrine hydrochloride, 16 mg/kg body weight. The recrudescence rate on day 14 of follow up was unacceptably high (38%). In the second trial the dose given was 8 mg/kg 6 hourly for three doses. Of the 49 children followed up for 14 days, 47 became aparasitaemic—ie, the cure rate was 96%. In both trials the drug was very well tolerated. Halofantrine hydrochloride seems to be effective against P falciparumchloroquine sensitive and resistant strains in Africa.
Url:
DOI: 10.1016/S0140-6736(88)92539-1
Links to Exploration step
ISTEX:F1DC9DA2420EB79A2069C40B92D02E225FF59201Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>CLINICAL TRIALS WITH HALOFANTRINE HYDROCHLORIDE IN MALAWI</title><author><name sortKey="Wirima, J" sort="Wirima, J" uniqKey="Wirima J" first="J." last="Wirima">J. Wirima</name><affiliation><mods:affiliation>Kamuzu Central Hospital, Lilongwe, Malawi;, Malawi</mods:affiliation></affiliation></author><author><name sortKey="Molyneux, M E" sort="Molyneux, M E" uniqKey="Molyneux M" first="M. E." last="Molyneux">M. E. Molyneux</name><affiliation><mods:affiliation>Department of Tropical Medicine, Liverpool School of Tropical Medicine, Liverpool;, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Khoromana, C" sort="Khoromana, C" uniqKey="Khoromana C" first="C." last="Khoromana">C. Khoromana</name><affiliation><mods:affiliation>Department of Tropical Medicine, Liverpool School of Tropical Medicine, Liverpool;, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Gilles, H M" sort="Gilles, H M" uniqKey="Gilles H" first="H. M." last="Gilles">H. M. Gilles</name><affiliation><mods:affiliation>Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, United Kingdom</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:F1DC9DA2420EB79A2069C40B92D02E225FF59201</idno><date when="1988" year="1988">1988</date><idno type="doi">10.1016/S0140-6736(88)92539-1</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-4X2NCX15-9/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000A55</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000A55</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">CLINICAL TRIALS WITH HALOFANTRINE HYDROCHLORIDE IN MALAWI</title><author><name sortKey="Wirima, J" sort="Wirima, J" uniqKey="Wirima J" first="J." last="Wirima">J. Wirima</name><affiliation><mods:affiliation>Kamuzu Central Hospital, Lilongwe, Malawi;, Malawi</mods:affiliation></affiliation></author><author><name sortKey="Molyneux, M E" sort="Molyneux, M E" uniqKey="Molyneux M" first="M. E." last="Molyneux">M. E. Molyneux</name><affiliation><mods:affiliation>Department of Tropical Medicine, Liverpool School of Tropical Medicine, Liverpool;, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Khoromana, C" sort="Khoromana, C" uniqKey="Khoromana C" first="C." last="Khoromana">C. Khoromana</name><affiliation><mods:affiliation>Department of Tropical Medicine, Liverpool School of Tropical Medicine, Liverpool;, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Gilles, H M" sort="Gilles, H M" uniqKey="Gilles H" first="H. M." last="Gilles">H. M. Gilles</name><affiliation><mods:affiliation>Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, United Kingdom</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">The Lancet</title><title level="j" type="abbrev">LANCET</title><idno type="ISSN">0140-6736</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1988">1988</date><biblScope unit="volume">332</biblScope><biblScope unit="issue">8605</biblScope><biblScope unit="page" from="250">250</biblScope><biblScope unit="page" to="252">252</biblScope></imprint><idno type="ISSN">0140-6736</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0140-6736</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Abdominal pain</term><term>Airway epithelium</term><term>American society</term><term>Arterial pressure</term><term>Cell count</term><term>Clinical trials</term><term>Comparable efficacy</term><term>Cure rate</term><term>Diluent solution</term><term>Dwangwa</term><term>Falciparum</term><term>Falciparum chloroquine</term><term>Falciparum malana</term><term>First part</term><term>First study</term><term>Frusemide</term><term>Haemoglobin level</term><term>Halofantrine</term><term>Halofantrine hydrochloride</term><term>Inhaled</term><term>Inhaled corticosteroids</term><term>Inhaled frusemide</term><term>Laboratory data</term><term>Lake malawi</term><term>Lung diseases</term><term>Malawi</term><term>Older children</term><term>Oral frusemide</term><term>Parasitaemia</term><term>Parasite</term><term>Parasite counts</term><term>Phenanthrene methanol compound halofantrine</term><term>Phenanthrene methanol halofantrine</term><term>Placebo</term><term>Plasmodium</term><term>Plasmodium falciparum</term><term>Protective effect</term><term>Pulse rate</term><term>Random order</term><term>Recrudescence rate</term><term>Resistant strains</term><term>Same time intervals</term><term>Second part</term><term>Second screening test</term><term>Second trial</term><term>Single dose</term><term>Study days</term><term>Tanzanian border</term><term>Tropical medicine</term><term>Typical history</term><term>West shore</term><term>Younger children</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Two clinical trials of the phenanthrene methanol compound halofantrine in the treatment of Plasmodium falciparum were conducted in Malawi, in areas where the parasite was known to be chloroquine resistant. In the first trial all 46 patients had symptoms of malaria and parasite densities ranging from 2500/μl to 212 000/μl. They were given a single dose of halofantrine hydrochloride, 16 mg/kg body weight. The recrudescence rate on day 14 of follow up was unacceptably high (38%). In the second trial the dose given was 8 mg/kg 6 hourly for three doses. Of the 49 children followed up for 14 days, 47 became aparasitaemic—ie, the cure rate was 96%. In both trials the drug was very well tolerated. Halofantrine hydrochloride seems to be effective against P falciparumchloroquine sensitive and resistant strains in Africa.</div></front></TEI><istex><corpusName>elsevier</corpusName><keywords><teeft><json:string>frusemide</json:string><json:string>halofantrine</json:string><json:string>falciparum</json:string><json:string>inhaled</json:string><json:string>placebo</json:string><json:string>parasitaemia</json:string><json:string>malawi</json:string><json:string>plasmodium</json:string><json:string>dwangwa</json:string><json:string>inhaled frusemide</json:string><json:string>plasmodium falciparum</json:string><json:string>parasite</json:string><json:string>oral frusemide</json:string><json:string>tropical medicine</json:string><json:string>halofantrine hydrochloride</json:string><json:string>falciparum malana</json:string><json:string>study days</json:string><json:string>clinical trials</json:string><json:string>cure rate</json:string><json:string>diluent solution</json:string><json:string>single dose</json:string><json:string>lung diseases</json:string><json:string>tanzanian border</json:string><json:string>cell count</json:string><json:string>phenanthrene methanol halofantrine</json:string><json:string>comparable efficacy</json:string><json:string>lake malawi</json:string><json:string>american society</json:string><json:string>younger children</json:string><json:string>laboratory data</json:string><json:string>abdominal pain</json:string><json:string>older children</json:string><json:string>haemoglobin level</json:string><json:string>west shore</json:string><json:string>first study</json:string><json:string>resistant strains</json:string><json:string>parasite counts</json:string><json:string>airway epithelium</json:string><json:string>first part</json:string><json:string>falciparum chloroquine</json:string><json:string>second part</json:string><json:string>second trial</json:string><json:string>protective effect</json:string><json:string>inhaled corticosteroids</json:string><json:string>arterial pressure</json:string><json:string>pulse rate</json:string><json:string>second screening test</json:string><json:string>same time intervals</json:string><json:string>recrudescence rate</json:string><json:string>random order</json:string><json:string>phenanthrene methanol compound halofantrine</json:string><json:string>typical history</json:string></teeft></keywords><author><json:item><name>J. Wirima</name><affiliations><json:string>Kamuzu Central Hospital, Lilongwe, Malawi;, Malawi</json:string></affiliations></json:item><json:item><name>M.E. Molyneux</name><affiliations><json:string>Department of Tropical Medicine, Liverpool School of Tropical Medicine, Liverpool;, United Kingdom</json:string></affiliations></json:item><json:item><name>C. Khoromana</name><affiliations><json:string>Department of Tropical Medicine, Liverpool School of Tropical Medicine, Liverpool;, United Kingdom</json:string></affiliations></json:item><json:item><name>H.M. Gilles</name><affiliations><json:string>Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, United Kingdom</json:string></affiliations></json:item></author><arkIstex>ark:/67375/6H6-4X2NCX15-9</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>Full-length article</json:string></originalGenre><abstract>Abstract: Two clinical trials of the phenanthrene methanol compound halofantrine in the treatment of Plasmodium falciparum were conducted in Malawi, in areas where the parasite was known to be chloroquine resistant. In the first trial all 46 patients had symptoms of malaria and parasite densities ranging from 2500/μl to 212 000/μl. They were given a single dose of halofantrine hydrochloride, 16 mg/kg body weight. The recrudescence rate on day 14 of follow up was unacceptably high (38%). In the second trial the dose given was 8 mg/kg 6 hourly for three doses. Of the 49 children followed up for 14 days, 47 became aparasitaemic—ie, the cure rate was 96%. In both trials the drug was very well tolerated. Halofantrine hydrochloride seems to be effective against P falciparumchloroquine sensitive and resistant strains in Africa.</abstract><qualityIndicators><score>6.377</score><pdfWordCount>2781</pdfWordCount><pdfCharCount>16712</pdfCharCount><pdfVersion>1.2</pdfVersion><pdfPageCount>3</pdfPageCount><pdfPageSize>614 x 898 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractWordCount>133</abstractWordCount><abstractCharCount>832</abstractCharCount><keywordCount>0</keywordCount></qualityIndicators><title>CLINICAL TRIALS WITH HALOFANTRINE HYDROCHLORIDE IN MALAWI</title><pmid><json:string>2899238</json:string></pmid><pii><json:string>S0140-6736(88)92539-1</json:string></pii><genre><json:string>research-article</json:string></genre><host><title>The Lancet</title><language><json:string>unknown</json:string></language><publicationDate>1988</publicationDate><issn><json:string>0140-6736</json:string></issn><pii><json:string>S0140-6736(00)X4261-4</json:string></pii><volume>332</volume><issue>8605</issue><pages><first>250</first><last>252</last></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date><json:string>2500</json:string><json:string>1988</json:string><json:string>3000</json:string></date><geogName></geogName><orgName><json:string>World Health Organisation Advances</json:string><json:string>Dwangwa Sugar Corporation</json:string><json:string>Hospital of Garbagnate Milanese</json:string><json:string>Clinical and Laboratory Data The</json:string><json:string>and Institute of Lung Diseases, University of Milano</json:string><json:string>Institute of Lung Diseases, University of Siena</json:string><json:string>Italy To</json:string><json:string>University of Liverpool</json:string><json:string>Department of Pharmacology and Therapeutics</json:string><json:string>American Society of Tropical Medicine and Hygiene</json:string><json:string>Clinical and Laboratory Data</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName></persName><placeName><json:string>Calgary</json:string><json:string>Vietnam</json:string><json:string>San Antonio</json:string><json:string>Thailand</json:string><json:string>Brescia</json:string><json:string>Bangkok</json:string><json:string>Canada</json:string><json:string>Kenya</json:string><json:string>Liverpool</json:string><json:string>France</json:string><json:string>Italy</json:string></placeName><ref_url></ref_url><ref_bibl><json:string>Agents and Chemotherapy 1973</json:string><json:string>May, 1986</json:string><json:string>March, 1987</json:string><json:string>American Association for Clinical Chemistry, July, 1977</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/6H6-4X2NCX15-9</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - medicine, general & internal</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - clinical medicine</json:string><json:string>3 - general & internal medicine</json:string></scienceMetrix><scopus><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - General Medicine</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string><json:string>4 - generalites</json:string></inist></categories><publicationDate>1988</publicationDate><copyrightDate>1988</copyrightDate><doi><json:string>10.1016/S0140-6736(88)92539-1</json:string></doi><id>F1DC9DA2420EB79A2069C40B92D02E225FF59201</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-4X2NCX15-9/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-4X2NCX15-9/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/6H6-4X2NCX15-9/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a">CLINICAL TRIALS WITH HALOFANTRINE HYDROCHLORIDE IN MALAWI</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher scheme="https://scientific-publisher.data.istex.fr">ELSEVIER</publisher><availability><licence><p>elsevier</p></licence></availability><p scheme="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-HKKZVM7B-M"></p><date>1988</date></publicationStmt><notesStmt><note type="research-article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</note><note type="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a">CLINICAL TRIALS WITH HALOFANTRINE HYDROCHLORIDE IN MALAWI</title><author xml:id="author-0000"><persName><forename type="first">J.</forename><surname>Wirima</surname></persName><affiliation>Kamuzu Central Hospital, Lilongwe, Malawi;, Malawi</affiliation></author><author xml:id="author-0001"><persName><forename type="first">M.E.</forename><surname>Molyneux</surname></persName><affiliation>Department of Tropical Medicine, Liverpool School of Tropical Medicine, Liverpool;, United Kingdom</affiliation></author><author xml:id="author-0002"><persName><forename type="first">C.</forename><surname>Khoromana</surname></persName><affiliation>Department of Tropical Medicine, Liverpool School of Tropical Medicine, Liverpool;, United Kingdom</affiliation></author><author xml:id="author-0003"><persName><forename type="first">H.M.</forename><surname>Gilles</surname></persName><affiliation>Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, United Kingdom</affiliation></author><idno type="istex">F1DC9DA2420EB79A2069C40B92D02E225FF59201</idno><idno type="ark">ark:/67375/6H6-4X2NCX15-9</idno><idno type="DOI">10.1016/S0140-6736(88)92539-1</idno><idno type="PII">S0140-6736(88)92539-1</idno></analytic><monogr><title level="j">The Lancet</title><title level="j" type="abbrev">LANCET</title><idno type="pISSN">0140-6736</idno><idno type="PII">S0140-6736(00)X4261-4</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1988"></date><biblScope unit="volume">332</biblScope><biblScope unit="issue">8605</biblScope><biblScope unit="page" from="250">250</biblScope><biblScope unit="page" to="252">252</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1988</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Abstract: Two clinical trials of the phenanthrene methanol compound halofantrine in the treatment of Plasmodium falciparum were conducted in Malawi, in areas where the parasite was known to be chloroquine resistant. In the first trial all 46 patients had symptoms of malaria and parasite densities ranging from 2500/μl to 212 000/μl. They were given a single dose of halofantrine hydrochloride, 16 mg/kg body weight. The recrudescence rate on day 14 of follow up was unacceptably high (38%). In the second trial the dose given was 8 mg/kg 6 hourly for three doses. Of the 49 children followed up for 14 days, 47 became aparasitaemic—ie, the cure rate was 96%. In both trials the drug was very well tolerated. Halofantrine hydrochloride seems to be effective against P falciparumchloroquine sensitive and resistant strains in Africa.</p></abstract></profileDesc><revisionDesc><change when="1988">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-4X2NCX15-9/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Elsevier, elements deleted: tail"><istex:xmlDeclaration>version="1.0" encoding="utf-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//ES//DTD journal article DTD version 4.5.2//EN//XML" URI="art452.dtd" name="istex:docType"></istex:docType><istex:document><converted-article version="4.5.2" docsubtype="fla"><item-info><jid>LANCET</jid><aid>88925391</aid><ce:pii>S0140-6736(88)92539-1</ce:pii><ce:doi>10.1016/S0140-6736(88)92539-1</ce:doi><ce:copyright type="unknown" year="1988"></ce:copyright></item-info><head><ce:title>CLINICAL TRIALS WITH HALOFANTRINE HYDROCHLORIDE IN MALAWI</ce:title><ce:author-group><ce:author><ce:given-name>J.</ce:given-name><ce:surname>Wirima</ce:surname><ce:cross-ref refid="ART5-AFF1"><ce:sup>a</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>M.E.</ce:given-name><ce:surname>Molyneux</ce:surname><ce:cross-ref refid="ART5-AFF2"><ce:sup>b</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>C.</ce:given-name><ce:surname>Khoromana</ce:surname><ce:cross-ref refid="ART5-AFF2"><ce:sup>b</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>H.M.</ce:given-name><ce:surname>Gilles</ce:surname><ce:cross-ref refid="ART5-AFF3"><ce:sup>c</ce:sup></ce:cross-ref></ce:author><ce:affiliation id="ART5-AFF1"><ce:label>a</ce:label><ce:textfn>Kamuzu Central Hospital, Lilongwe, Malawi;, Malawi</ce:textfn></ce:affiliation><ce:affiliation id="ART5-AFF2"><ce:label>b</ce:label><ce:textfn>Department of Tropical Medicine, Liverpool School of Tropical Medicine, Liverpool;, United Kingdom</ce:textfn></ce:affiliation><ce:affiliation id="ART5-AFF3"><ce:label>c</ce:label><ce:textfn>Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, United Kingdom</ce:textfn></ce:affiliation></ce:author-group><ce:abstract><ce:section-title>Abstract</ce:section-title><ce:abstract-sec><ce:simple-para>Two clinical trials of the phenanthrene methanol compound halofantrine in the treatment of <ce:italic>Plasmodium falciparum</ce:italic> were conducted in Malawi, in areas where the parasite was known to be chloroquine resistant. In the first trial all 46 patients had symptoms of malaria and parasite densities ranging from 2500/μl to 212 000/μl. They were given a single dose of halofantrine hydrochloride, 16 mg/kg body weight. The recrudescence rate on day 14 of follow up was unacceptably high (38%). In the second trial the dose given was 8 mg/kg 6 hourly for three doses. Of the 49 children followed up for 14 days, 47 became aparasitaemic—ie, the cure rate was 96%. In both trials the drug was very well tolerated. Halofantrine hydrochloride seems to be effective against <ce:italic>P falciparum</ce:italic>chloroquine sensitive and resistant strains in Africa.</ce:simple-para></ce:abstract-sec></ce:abstract></head></converted-article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo><title>CLINICAL TRIALS WITH HALOFANTRINE HYDROCHLORIDE IN MALAWI</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>CLINICAL TRIALS WITH HALOFANTRINE HYDROCHLORIDE IN MALAWI</title></titleInfo><name type="personal"><namePart type="given">J.</namePart><namePart type="family">Wirima</namePart><affiliation>Kamuzu Central Hospital, Lilongwe, Malawi;, Malawi</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.E.</namePart><namePart type="family">Molyneux</namePart><affiliation>Department of Tropical Medicine, Liverpool School of Tropical Medicine, Liverpool;, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C.</namePart><namePart type="family">Khoromana</namePart><affiliation>Department of Tropical Medicine, Liverpool School of Tropical Medicine, Liverpool;, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H.M.</namePart><namePart type="family">Gilles</namePart><affiliation>Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="Full-length article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1988</dateIssued><copyrightDate encoding="w3cdtf">1988</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><abstract lang="en">Abstract: Two clinical trials of the phenanthrene methanol compound halofantrine in the treatment of Plasmodium falciparum were conducted in Malawi, in areas where the parasite was known to be chloroquine resistant. In the first trial all 46 patients had symptoms of malaria and parasite densities ranging from 2500/μl to 212 000/μl. They were given a single dose of halofantrine hydrochloride, 16 mg/kg body weight. The recrudescence rate on day 14 of follow up was unacceptably high (38%). In the second trial the dose given was 8 mg/kg 6 hourly for three doses. Of the 49 children followed up for 14 days, 47 became aparasitaemic—ie, the cure rate was 96%. In both trials the drug was very well tolerated. Halofantrine hydrochloride seems to be effective against P falciparumchloroquine sensitive and resistant strains in Africa.</abstract><relatedItem type="host"><titleInfo><title>The Lancet</title></titleInfo><titleInfo type="abbreviated"><title>LANCET</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1988</dateIssued></originInfo><identifier type="ISSN">0140-6736</identifier><identifier type="PII">S0140-6736(00)X4261-4</identifier><part><date>1988</date><detail type="issue"><title>Originally published as Volume 2, Issue 8605</title></detail><detail type="volume"><number>332</number><caption>vol.</caption></detail><detail type="issue"><number>8605</number><caption>no.</caption></detail><extent unit="issue-pages"><start>235</start><end>292</end></extent><extent unit="pages"><start>250</start><end>252</end></extent></part></relatedItem><identifier type="istex">F1DC9DA2420EB79A2069C40B92D02E225FF59201</identifier><identifier type="ark">ark:/67375/6H6-4X2NCX15-9</identifier><identifier type="DOI">10.1016/S0140-6736(88)92539-1</identifier><identifier type="PII">S0140-6736(88)92539-1</identifier><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-HKKZVM7B-M">elsevier</recordContentSource></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-4X2NCX15-9/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A55 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000A55 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:F1DC9DA2420EB79A2069C40B92D02E225FF59201
|texte= CLINICAL TRIALS WITH HALOFANTRINE HYDROCHLORIDE IN MALAWI
}}
| This area was generated with Dilib version V0.6.33. |  |